加载中
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
常规交易时段
US$51.72
−US$1.72 · -3.22%
盘中时间采用ET。市场数据可能有所延迟。
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
日内区间
当前US$51.72
52周区间
当前US$51.72
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
78
低估
情绪
58
多空交织
风险
37
中等风险
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
日内区间
当前US$51.72
52周区间
当前US$51.72
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.96亿0.01%2.3万亿 USD0.03%US$379.94-0.29%
State Street SPDR S&P Biotech ETFXBI1.31亿1.27%100.75亿 USD0.35%US$146.41-2.55%
iShares Russell 2000 ETFIWM1.25亿0.16%785.63亿 USD0.19%US$275.25-0.88%
Vanguard Extended Market ETFVXF7161.33万0.07%954亿 USD0.05%US$231.97-0.65%
iShares Russell 2000 Growth ETFIWO4466.97万0.32%142.49亿 USD0.24%US$351.02-1.22%
iShares Biotechnology ETFIBB3693.63万0.35%104.01亿 USD0.44%US$197.34-2.95%
Vanguard Russell 2000 ETFVTWO3406.23万0.19%180亿 USD0.06%US$111.17-0.93%
Schwab U.S. Small-Cap ETFSCHA2750.86万0.13%216.99亿 USD0.03%US$32.37-0.74%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
